Legend Bio Starts US Trial of CD4 CAR-T Therapy for Lymphoma
publication date: Sep 13, 2021
Nanjing Legend Biotech has started a US Phase 1 trial of its autologous CD4 CAR-T therapy for lymphoma. The trial will enroll adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). LB1901 targets CD4, a surface membrane glycoprotein expressed in most TCL subtypes. Legend's lead candidate, cilta-cel, is a BCMA-targeted CAR-T for multiple myeloma that is under review for marketing approval in China, the US and EU. Legend partnered cilta-cel with Janssen Pharma. More details....
Stock Symbol: (NSDQ: LEGN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.